Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rosuvastatin

rosuvastatin

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rosuvastatin

68 trials tracked of rosuvastatin: 32 in phase 3 or 4 and 9 with published results. The most-cited published study has 161 citations.

68Trials tracked
32Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 11 Phase 3 21 Phase 2 9 Phase 1 24 Other / NA 3
  1. Phase 3 Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD Completed · 161 cited
  2. Phase 4 Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Completed · 86 cited
  3. Phase 3 Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Completed · 49 cited
  4. Phase 3 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia Completed · 39 cited
  5. Phase 3 A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis Completed · 38 cited
  6. Phase 3 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Completed · 31 cited
Show 44 more trials
  1. Phase 4 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Completed · 9 cited
  2. Phase 3 Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy Completed · 8 cited
  3. Phase 3 Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) Completed · 2 cited
  4. Phase 4 CYP2B6 Genetics and Drug Interactions in Healthy Volunteers Completed
  5. Phase 4 Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2) Completed
  6. Phase 4 Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients Completed
  7. Phase 4 Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease Completed
  8. Phase 4 Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients Completed
  9. Phase 4 Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED) Completed
  10. Phase 4 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed
  11. Phase 4 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed
  12. Phase 4 A Diabetes Study to Treat A Population Previously Not at Target Completed
  13. Phase 3 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833) Completed
  14. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  15. Phase 3 A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia Completed
  16. Phase 3 PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin Completed
  17. Phase 3 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease Completed
  18. Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 Completed
  19. Phase 3 Rosuvastatin in Visceral Adiposity Completed
  20. Phase 3 CRESTOR Athero Imaging Head to Head IVUS Study Completed
  21. Phase 3 Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia Completed
  22. Phase 3 Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) Completed
  23. Phase 3 An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia Completed
  24. Phase 3 A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia Completed
  25. Phase 3 Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I) Completed
  26. Phase 3 Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED) Completed
  27. Phase 2 Supplements, Placebo, or Rosuvastatin Study Completed
  28. Phase 2 Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease Completed
  29. Phase 2 Pilot Trial of Statin Use in Burn Patients Completed
  30. Phase 2 Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease Completed
  31. Phase 2 YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering Completed
  32. Phase 2 Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer Completed
  33. Phase 2 Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease Completed
  34. Phase 2 High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV Completed
  35. Phase 2 A Study of LY2484595 in Patients With High LDL-C or Low HDL-C Completed
  36. Phase 1 Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Completed
  37. Phase 1 Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions Completed
  38. Phase 1 A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults Completed
  39. Phase 1 Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants Completed
  40. Phase 1 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin Completed
  41. Phase 1 A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood Completed
  42. Phase 1 A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood Completed
  43. Phase 1 This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men Completed
  44. Phase 1 Transporter Cocktail Mutual Interaction Completed

Showing the 50 most-cited and recently-updated of 68 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Cerivastatin best for total cholesterol, simvastatin for LDL-C in DKD with hyperlipidemia
Diabetes & Endocrinology Meta-analysis
Cerivastatin best for total cholesterol, simvastatin for LDL-C in DKD with hyperlipidemia Lipid-Lowering Drugs Show Different Benefits for Kidney Disease
A network meta-analysis of 20 RCTs in patients with diabetic kidney disease and hyperlipidemia found that cerivastatin most effectively redu…
A review of 20 trials found that different statins and fenofibrate have unique effects on cholesterol, kidney markers, and heart risks in di…
Frontiers May 29, 2026
FDA Approves Crestor (rosuvastatin) for Cardiovascular Risk Reduction in Adults
Cardiology FDA Approval
FDA Approves Crestor (rosuvastatin) for Cardiovascular Risk Reduction in Adults FDA approves Crestor to prevent heart attacks and strokes in certain adults.
FDA approved Crestor (rosuvastatin) to reduce risk of major adverse cardiovascular events in adults without established coronary heart disea…
The FDA approved Crestor (rosuvastatin) to reduce the risk of heart attack, stroke, and related events in adults without heart disease but w…
FDA May 5, 2026
Very high-intensity statin with ezetimibe lowers LDL-C more than high-intensity regimen after AMI
Cardiology RCT
Very high-intensity statin with ezetimibe lowers LDL-C more than high-intensity regimen after AMI Can a stronger statin dose after a heart attack lower cholesterol more?
A single-center RCT of 220 AMI patients compared very high-intensity vs.
A stronger statin dose after a heart attack lowers bad cholesterol better but causes more side effects, forcing some patients to cut back on…
Apr 3, 2026